Hereditary transthyretin amyloidosis (HTA) Program in Pharmaceutical Benefits Scheme (PBS) 012-24070419

HTA restriction and item codes

Do not share this attachment externally. See Freedom of Information - Information Publication Scheme.

PBS HTA restriction and item codes

PBS Complex Drugs Programs

Table 1: see Table 2 in Processing Complex Authority Required Listings for FAQs about all Complex programs.

Item	Description
1	Is there an age restriction for patients applying for PBS-subsidised treatment of HTA? Patients must be aged 18 years or older.
2	Is there a change restriction for patients switching between PBS-subsidised patisiran and vutrisiran for HTA? No, there is no change restriction for HTA. Prescribers must apply using the initial restriction (and the initial form if they choose not to self-serve) for the change.
3	Are hospital details required for authority applications for patisiran or vutrisiran? Yes. Hospital details: are required because patisiran and vutrisiran are PBS-subsidised under Section 100 arrangements for Highly Specialised Drugs (HSD) Program must be provided for each application for S100 HSD
4	Can increased quantity and/or repeats be authorised for patisiran or vutrisiran? No increase (NO INC) in the PBS-listed maximum quantity and repeats are allowed for this item.